LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New proton beam strategy aims to tame tough pancreatic tumors
Disease control Recruiting nowThis study tests a new way of giving radiation called PULSAR, which delivers short, powerful proton beam pulses spaced weeks apart. The goal is to better control pancreatic tumors while reducing side effects. About 47 adults with locally advanced or limited spread pancreatic canc…
Matched conditions: LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New combo therapy aims to tame tough pancreatic tumors
Disease control Recruiting nowThis early-stage study tests a drug called XER-001 given through a tube into the small intestine, combined with precise radiation, for people with locally advanced pancreatic cancer. The goal is to find the safest dose and see if the treatment can control the tumor. About 36 adul…
Matched conditions: LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Xerient Pharma • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New hope for pancreatic cancer: immune boosting drug combo trial launches
Disease control Recruiting nowThis study tests whether adding two new drugs (zimberelimab and quemliclustat) to standard chemotherapy can help shrink pancreatic tumors that are either borderline removable or have spread locally. The goal is to make surgery possible and improve survival. About 56 adults with u…
Matched conditions: LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC
-
New MRI scan could predict pancreatic cancer treatment success
Diagnosis Recruiting nowThis study tests a new type of MRI scan that uses a special contrast agent (hyperpolarized carbon-13 pyruvate) to see how pancreatic tumors process nutrients. The goal is to predict whether treatment is working earlier than standard scans. The study involves 70 adults with advanc…
Matched conditions: LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated May 14, 2026 12:01 UTC
-
Genetic clues could unlock better pancreatic cancer care
Knowledge-focused Recruiting nowThis study looks at whether genetic information from tumors can help doctors choose the right treatment for pancreatic cancer. About 200 people with early or locally advanced pancreatic cancer will give blood and tissue samples while receiving standard chemotherapy. Researchers w…
Matched conditions: LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated May 16, 2026 23:50 UTC
-
New drug OMO-103 studied in pancreatic cancer patients to reveal tumor changes
Knowledge-focused Recruiting nowThis early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic disease. The main goal is to see if the drug causes measurable changes in the tumor's biology by comparing tissue samples taken before and after tr…
Matched conditions: LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 16, 2026 23:49 UTC
-
New study peeks inside pancreatic tumors to find better drug targets
Knowledge-focused Recruiting nowThis study is for people with pancreatic cancer that can be removed by surgery or has spread. Researchers will give one of several drugs (cobimetinib, olaparib, onvansertib, azenosertib, AZD5305, or tremelimumab) for a short time before surgery or biopsy. By comparing tumor sampl…
Matched conditions: LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 16, 2026 23:47 UTC